Drotrecogin Alfa Dosage

Usual Adult Dose for Sepsis

Drotrecogin alfa was voluntarily withdrawn from the market by the manufacturer in October, 2011 due to failure to show a survival benefit for patients with severe sepsis and septic shock. The following dosage information applies to when the drug was available in the U.S.

24 mcg/kg/hr by intravenous infusion for 96 hours

Usual Pediatric Dose for Sepsis

Drotrecogin alfa was voluntarily withdrawn from the market by the manufacturer in October, 2011 due to failure to show a survival benefit for patients with severe sepsis and septic shock. The following dosage information applies to when the drug was available in the U.S.

Multiple study data:
0 to 18 years: 24 mcg/kg/hr by intravenous infusion for 96 hours.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Use with caution in patients with chronic severe hepatic disease due to increased risk of bleeding.

Dose Adjustments

If the infusion is interrupted, restart at 24 mcg/kg/hr. Do not bolus or increase dose.

Precautions

Stop infusion if bleeding occurs.

Drotrecogin alfa may prolong APTT. Prothrombin time (PT) is recommended for monitoring the status of coagulopathy.

There are no data on the safety and efficacy of administering more than 1 course of drotrecogin alfa to septic patients.

Efficacy has not been established in septic patients with a lower risk of death (APACHE II score<25).

Safety and efficacy have not been established in children <18 years.

Dialysis

Data not available

Other Comments

The infusion should be stopped if clinically significant bleeding occurs. Reinitiation of drotrecogin alfa may be considered after hemostasis is achieved.

Drotrecogin alfa should be discontinued 2 hours before surgery or procedures with a risk of bleeding. Reinitiation may be considered 12 hours after the procedure if hemostasis has been achieved.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer